BIOSENSORS INTERNATIONAL released the primary endpoint data of LEADERS FREE II, the critical US trial of its flagship product BioFreedom
發布時間：2019-8-1
On September 22, 2018, at
the Main Arena of the annual academic conference of Transcatheter
Cardiovascular Therapeutics (TCT) 2018 in San Diego, California, USA, BIOSENSORS
INTERNATIONAL, the parent company of JWMS, announced the results of the primary
endpoint of its world-renowned LEADERS FREE II trial. This new study confirmed
the reproducibility of previous good results of European LEADERS FREE trials,
which could lead to wider clinical practice on HBR patients in North America